

Carcinoma Transitional Cell

[View the current Carcinoma Transitional Cell InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Carcinoma_Transitional_Cell.html) (PDF)

(http://www.bioportfolio.com/indepth/Carcinoma_Transitional_Cell.html) - Regularly Updated.

Recent Publications on Carcinoma Transitional Cell:



- [Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.](#)
PURPOSE: Vinflunine (VFL) is a new microtubule inhibitor that has activity...5th November, 2009
Department of Medical Oncology, University Hospital Del Mar, Passeig- J Clin Oncol. 2009 Sep 20;27(27):4454-61. Epub 2009 Aug 17. ([DOI Direct Link](#))
- [Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?](#)
PURPOSE: Vinflunine (VFL) is a new microtubule inhibitor that has activity...5th November, 2009
- J Clin Oncol. 2009 Sep 20;27(27):4444-5. Epub 2009 Aug 17. ([DOI Direct Link](#))
- [\[Response to adjuvant chemotherapy after radical cystectomy in patients with infiltrative bladder: Analysis of 397 cases\]](#)
OBJECTIVES: To define the usefulness of adjuvant chemo-therapy in patients...3rd November, 2009
Hospital General Universitario Gregorio Maranon, Madrid, Espana.- Arch Esp Urol. 2009 May;62(4):275-82.
- [Diagnosis and treatment of bladder cancer.](#)
*Bladder cancer is the sixth most prevalent malignancy in the United...*31st October, 2009
Department of Family Medicine at Creighton University School of Medicine- Am Fam Physician. 2009 Oct 1;80(7):717-23.
- [Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.](#)
PURPOSE: A factor pertinent to the design of cancer chemotherapy is...31st October, 2009
Department of Biomedical Sciences, University of Portsmouth, Portsmouth,- J Urol. 2009 Nov;182(5):2472-6. Epub 2009 Sep 17. ([DOI Direct Link](#))
- [Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.](#)
PURPOSE: The prognostic significance of renal pelvis vs ureteral upper...31st October, 2009
Cancer Prognostics and Health Outcomes Unit, University of Montreal,- J Urol. 2009 Nov;182(5):2177-81. Epub 2009 Sep 16. ([DOI Direct Link](#))
- [Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy.](#)
PURPOSE: Lymph node metastasis in patients who undergo radical cystectomy...31st October, 2009
Department of Urology, Keck School of Medicine, University of Southern- J Urol. 2009 Nov;182(5):2182-7. Epub 2009 Sep 15. ([DOI Direct Link](#))
- [\[Upper urinary tract transitional cell carcinoma: current treatment options and minimally invasive approaches\]](#)
OBJECTIVES: Upper urinary tract transitional cell carcinoma (UUT-TCC) is a...29th October, 2009

Unidad de Endourologia y Laparoscopia Urologica, Clinica Santa Maria, Las- Arch Esp Urol. 2009 Jun;62(5):367-75.

- [Editorial comment.](#)
*Bladder cancer is the sixth most prevalent malignancy in the United...*24th October, 2009
- Urology. 2009 Oct;74(4):957. ([DOI Direct Link](#))
- [Editorial comment.](#)
*Bladder cancer is the sixth most prevalent malignancy in the United...*24th October, 2009
- Urology. 2009 Oct;74(4):864-5; author reply 865. ([DOI Direct Link](#))
- [Penile metastasis from invasive bladder cancer.](#)
*OBJECTIVE: To present the rare case of penile metastasis from bladder...*22nd October, 2009
Clinical Center of Serbia, Urological Clinic, Belgrade, Serbia.- Acta Chir Jugosl. 2009;56(2):101-3.
- [Primary papillary transitional cell carcinoma of the breast: a case report.](#)
*BACKGROUND: Primary papillary transitional cell carcinoma of the breast is...*15th October, 2009
Department of Histopathology, Nnamdi Azikiwe University Teaching Hospital,- Niger J Clin Pract. 2009 Jun;12(2):219-20.
- [Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.](#)
*OBJECTIVE: To present the rare case of penile metastasis from bladder...*3rd October, 2009
Hematology-Oncology Division, Department of Medicine, Massachusetts- N Engl J Med. 2009 Sep 24;361(13):1292-9. ([DOI Direct Link](#))
- [Editorial comment.](#)
*PURPOSE: Vinflunine (VFL) is a new microtubule inhibitor that has activity...*3rd October, 2009
Department of Urology, Stanford University School of Medicine, Stanford,- J Urol. 2009 Oct;182(4):1311-2. Epub 2009 Aug 14. ([DOI Direct Link](#))
- [Re: Palou et al.: Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. \(Urology 2009;73:1313-1317\).](#)
*OBJECTIVES: To define the usefulness of adjuvant chemo-therapy in patients...*17th September, 2009
- Urology. 2009 Sep;74(3):714. ([DOI Direct Link](#))

BioNews Results for Carcinoma Transitional Cell

- [Incidental Diagnosis of Transitional Cell Carcinoma during Percutaneous Nephrolithotomy](#)
MDLinx: Oct 14 2009 11:21AM Matching: carcinoma transitional cell

Carcinoma Transitional Cell Clinical Trials:



- [Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder](#)



Carcinoma Transitional Cell Patents:

- 7465720- [Proteasome inhibiting .beta.-lactam compounds](#)
- 7507748- [Substituted aryl-amine derivatives and methods of use](#)
- 7507795- [Murine ZCYTOR17 ligand polypeptides](#)
- 7507858- [Histone deacetylase inhibitors](#)
- 7511156- [Analogues of Salinosporamide A](#)
- 7527969- [RAAG10 cell surface target and a family of antibodies recognizing that target](#)
- 7528137- [Compounds, compositions, and methods](#)
- 7528142- [Aminopyrimidines useful as kinase inhibitors](#)
- 7531526- [Boronic ester and acid compounds, synthesis and uses](#)
- 7531636- [Antibodies to murine zcytor17 ligand](#)
- 7534918- [Histone deacetylase inhibitors](#)
- 7507724- [Therapy-enhancing glucan](#)
- 7504413- [N-\(4-\(imidazo\[1,2A\]pyridin-YL\)phenethyl\)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases](#)
- 7501435- [Inhibitors of checkpoint kinases](#)
- 7465746- [Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP](#)
- 7470509- [Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer](#)
- 7473528- [Method for the detection of Chagas disease related gene transcripts in blood](#)
- 7476743- [Compounds, compositions, and methods](#)
- 7482343- [Compounds, methods and compositions](#)
- 7485649- [Inhibitors of checkpoint kinases](#)
- 7491746- [Compounds, compositions and methods](#)
- 7494804- [Polynucleotide encoding cytokine receptor zcytor17 multimer](#)
- 7495102- [Azaindole inhibitors of aurora kinases](#)
- 7498416- [Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof](#)
- 7544677- [Inhibitors of Akt activity](#)
- 7544695- [Spirocyclic compounds](#)
- 7579355- [Inhibitors of Akt activity](#)
- 7579473- [c-Met modulators and methods of use](#)
- 7582668- [Imidazolyl-benzamide anti-cancer agents](#)
- 7589066- [Potent and specific immunoproteasome inhibitors](#)
- 7589068- [Inhibitors of Akt activity](#)
- 7589098- [Methods and compositions utilizing quinazolinones](#)
- 7589118- [IAP BIR domain binding compounds](#)
- 7595337- [Mitotic kinesin inhibitors](#)
- 7605266- [Azaindole inhibitors of Aurora kinases](#)
- 7608643- [Compounds for inhibiting KSP kinesin activity](#)
- 7579320- [IAP BIR domain binding compounds](#)
- 7576209- [Inhibitors of Akt activity](#)
- 7576074- [Receptor-type kinase modulators and methods of use](#)
- 7547724- [IAP BIR domain binding compounds](#)
- 7550477- [Inhibitors of checkpoint kinases](#)

- 7550478- [Tyrosine kinase inhibitors](#)
- 7550496- [Compositions and methods for treating cancer](#)
- 7553838- [Mitotic kinesin inhibitors](#)
- 7557115- [Compounds, compositions, and methods](#)
- 7569672- [Antibodies that bind to EphA2 and methods of use thereof](#)
- 7572814- [3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds](#)
- 7572895- [Transferrin receptor antibodies](#)
- 7572896- [Antibodies to oncostatin M receptor](#)
- 7608739- [Mitotic kinesin inhibitors](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

